A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)

Trial Profile

A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions
  • Acronyms Brilinta DaYu
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
    • 02 Feb 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top